Literature DB >> 26177716

Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery.

Caroline M J van Kinschot1, Nielka P van Erp2, Tanja Feberwee3, Vincent O Dezentjé4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26177716     DOI： 10.1007/s00228-015-1902-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  10 in total

1.  A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

Authors:  Nielka P van Erp; Djoeke de Wit; Henk-Jan Guchelaar; Hans Gelderblom; Trees J Hessing; Jan den Hartigh
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-08-17       Impact factor: 3.205

2.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

3.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Authors:  R J Motzer; M Mazumdar; J Bacik; W Berg; A Amsterdam; J Ferrara
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

4.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

5.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Authors:  Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

Review 6.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

Review 7.  Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

Authors:  Val R Adams; Markos Leggas
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

8.  Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.

Authors:  D de Wit; H Gelderblom; A Sparreboom; J den Hartigh; M den Hollander; J M C König-Quartel; T Hessing; H J Guchelaar; N P van Erp
Journal:  Cancer Chemother Pharmacol       Date:  2013-10-23       Impact factor: 3.333

Review 9.  Clinical pharmacokinetics of tyrosine kinase inhibitors.

Authors:  Nielka P van Erp; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2009-09-05       Impact factor: 12.111

10.  Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.

Authors:  Djoeke de Wit; Nielka P van Erp; Reza Khosravan; Robin Wiltshire; Randy Allred; George D Demetri; Henk-Jan Guchelaar; Hans Gelderblom
Journal:  BMC Cancer       Date:  2014-08-08       Impact factor: 4.430
  10 in total
  2 in total

1.  Medication Management after Bariatric Surgery: Providing Optimal Patient Care.

Authors:  Daniel Porat; Arik Dahan
Journal:  J Clin Med       Date:  2020-05-17       Impact factor: 4.241

Review 2.  Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.

Authors:  Kim Westerdijk; Ingrid M E Desar; Neeltje Steeghs; Winette T A van der Graaf; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2020-01-21       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.